As AbbVie's Risankizumab Looms, Sun Pushes To 'Maximize Time' Of Ilumya
Executive Summary
Sun says that it is "excited" with Ilumya’ s initial launch uptake in the crowded US psoriasis segment, but is pushing ahead with "speedy execution" of plans for the product before the potential arrival of new rivals such as AbbVie’s same-class therapy risankizumab.
You may also be interested in...
Sun’s Ilumya Ramps Up In Skyrizi’s Shadow
Patient numbers and prescriptions in the US for Sun’s psoriasis therapy Ilumya are steadily on the rise, and the Indian firm said that the arrival of AbbVie’s rival Skyrizi hasn’t adversely impacted its formulary position.
AbbVie’s Humira Succession Plan Begins Taking Shape With Skyrizi US Approval
Central to AbbVie’s plans to endure biosimilar erosion to Humira, Skyrizi gets US approval in psoriasis, with approval of upadacitinib expected in RA this year.
Sun’s Ilumya Gnaws At US Psoriasis Market
Around 800 physicians have prescribed Sun’s Ilumya, giving it some early traction in the competitive US psoriasis market. The Indian firm is striving to push harder and will also take a call on pursuing additional indications for the product.